Oslo, 11 December 2023. Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo:
LYTIX), a clinical stage immuno-oncology company, today announces that data from
the ATLAS-IT-04 study has been published a paper entitled "LTX-315 and adoptive
cell therapy using tumor-infiltrating lymphocytes generate tumor specific T
cells in patients with metastatic soft tissue sarcoma". The paper is published
in OncoImmunology, a high-profile, open access journal covering tumor immunology
and immunotherapy. 

The ATLAS-IT-04 trial was an open label, Phase II trial assessing the effect of
LTX-315 when used in combination with Adoptive Cell Therapy (ACT) in patients
with progressive metastatic soft tissue sarcoma that had failed standard of care
of treatment.

The ATLAS-IT-04 trial included intra-tumoral injections of LTX-315 ahead of
surgical removal of tumors, followed by in vitro expansion of T cells isolated
from the resected tumor. In a second step, the expanded T cells were infused
back to the patients. Six heavily pretreated patients were included in the trial
and treated with LTX-315, of which four patients proceeded to adoptive T-cell
therapy. The treatment was safe, and the best overall clinical response was
stabilization of the disease for 208 days. The immune response data from the
trial demonstrated that the treatment induces tumor specific T cells in blood,
providing proof of concept that LTX-315 generates an immune response that
targets the tumor.

Dr. Øystein Rekdal, CEO of Lytix commented: "This Phase II study proofs that it
is feasible to combine LTX-315 and adoptive T-cell therapy and confirms that
LTX-315 can induce tumor specific immune responses resulting in stabilization of
the disease in sarcoma patients with otherwise progressive disease. This
proof-of-concept study in patients with an unmet medical need has given us
valuable information for further optimization and commercialization of our
technology platform."

The article can be found here:
https://www.tandfonline.com/doi/full/10.1080/2162402X.2023.2290900 

For more information, please contact: 
Gjest Breistein, CFO
E-Mail:gjest.breistein@lytixbiopharma.com

Optimum Strategic Communications
Nick Bastin, Jonathan Edwards
E-mail: lytix@optimumcomms.com

Lytix in brief: 
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
Company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class molecule representing a new and
superior therapeutic principle to kill cancer cells and boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapies. LTX-315 targets cancer cells and disintegrates their
cell membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens. This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors such as
PBM Capital, a US based, healthcare-focused investment firm.